Based on our advanced algorithm, we predict that CANF stock price will experience significant movement in the coming periods. Our 1-day prediction estimates a price of $0.98, while the 1-week outlook suggests a value of $1. For the 1-month forecast, we project a price of $1.06. Looking further ahead, our 2026 projection estimates a value of $0.00, with a long-term 2030 forecast reaching $0.00. Stay informed and make strategic decisions with our data-driven insights!
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. CANF has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
CANF stock price ended at $0.98 on Friday, after losing-2.97%
The Can Fite Biopharma Ltd stock price decreased by -2.97% on the last trading day (25 Jul 2025), dropping from 1.01 to 0.98. Throughout the last trading session, the stock experienced a fluctuation of 4.12% , ranging from a day low of $0.97 to a day high of 1.01. The price has declined in 5 of the last 10 days, resulting in a total change of -5.31% during this period. On the last day, trading volume increase by -293.72K shares, with the falling prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 234.84K shares were traded, amounting to approximately 231.60K.
CANF Technical Signals
CANF(Can Fite Biopharma Ltd Corp) has 2 buy signals and 5 sell signals now. The current trend is downtrend starting from 2025-05-05. The total price change during this trend is -14.78%. Recently, the price has decreased but the volume has also decreased, indicating a potential rebound signal. The average turnover of CANF over the last 5 trading days is 195.50K. Overall, the technical indicator signals lean more toward a Bearish outlook in the mid-term.
CANF Moving Average Analysis
Can Fite Biopharma Ltd's overall moving average trend leans more bearish as of Monday, July 28, 2025, with 4 negative signals and 0 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $1.07, and $1.10. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $0.97, and $0.94. A break-down below any of these levels will issue sell signals.
CANF Short Selling Analysis
The short sale ratio of Can Fite Biopharma Ltd(CANF) as of 25 Jul 2025 is 41.11%, rising from last trading day. With increasing price from 1.01 to 0.98. The short sell activity indicate that short sellers may be anticipating further declines.
Technical Signal
Technical Signals Summary
Sell
Sell
5
Buy
2
Moving Average
Swing
Negative
Stock Price Below SMA_5
Short Term
Negative
SMA_5 Below SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
2 Bullish Signals
2 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Commodity Channel Index (20 days, 0.015 constant)
CCI_20_0.015 < -100
-315.699
Bullish
Williams %R (14 days)
WILLR_14 < -80
-87.5
Bullish
5 Bearish Signals
5 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
In 2026, Can Fite Biopharma Ltd (CANF) is anticipated to change hands in a trading channel between $0.00 and $0.00.
Can Fite Biopharma Ltd Stock Forecast 2026
CANF Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Can Fite Biopharma Ltd(CANF), our algorithm predicts CANF's 1-month price at $1.10, with an 12%upwardshift. Using a similarity score up to 90.99%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Can Fite Biopharma Ltd (CANF.A) stock, as of Sunday, July 27, 2025 , forecasts a 12% change over the next month, based on its high correlation with ENPH.O stock patterns. The similarity between their price movements over the analyzed periods is 90.99%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
CANF
Future prediction
Up: 12%
ENPH
Up: 12%Similarity: 90.99%
Name
Similarity
Up/Down
ENPH.O
90.99%
+12.00%
WOW.N
90.91%
+34.44%
PMTS.O
90.86%
-18.81%
MCY.N
90.81%
-3.84%
SMBK.O
90.75%
+0.33%
CYCC.O
90.57%
-15.10%
MFH.O
90.14%
-3.83%
FTFT.O
90.07%
-19.43%
CALC.O
90.06%
+1.69%
BUD.N
90.01%
-6.07%
CANF Seasonality Analysis
Based on CANF's historical stock price data across all years, the probability of a positive return in July is14.29%, suggesting it maynotbe an ideal month to invest in CANF. In contrast,Mayoffers the highest probability of positive returns at50.00%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Can Fite Biopharma Ltd (CANF.A) stock in May has the highest probability of a positive return (50.00%), while January has the lowest probability (10.00%).
Performance Seasonality
The chart shows Can Fite Biopharma Ltd. (CANF)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
Should I buy Can Fite Biopharma Ltd (CANF.A) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. CANF has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
Which months have the highest win rate for buying Can Fite Biopharma Ltd (CANF.A) stock in a year?
The radar chart shows that buying Can Fite Biopharma Ltd (CANF.A) stock in May has the highest probability of a positive return (50.00%), while January has the lowest probability (10.00%).
How has Can Fite Biopharma Ltd. (CANF)'s stock price performed over the past three years?
CANF's stock price fell by -62.71% in 2023,decreased by -21.50% in 2024, and went down by 45.25%in 2025.
Bearish technical signals of CANF include: AO_5_34 < 0, MOM_10 < 0, MACD_12_26_9 < 0, close < fibonacci_S1, 10-day SMA crosses below 20-day SMA.
Is CANF a buy based on overall technical signals summary?
CANF has 2 buy signals and 5 sell signals now. Overall the technical rating for CANF is Sell . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of CANF.
What is the trend of Can Fite Biopharma Ltd (CANF)'s moving average?
Can Fite Biopharma Ltd's overall moving average trend leans more bearish as of July 28 2025, with 4 negative signals and 0 positive signal.
What is price prediction for CANF stock next month?
The price prediction chart for Can Fite Biopharma Ltd (CANF.A) stock, as of July 27 2025, forecasts a 12% change over the next month, based on its high correlation with ENPH stock patterns. The similarity between their price movements over the analyzed periods is 90.99%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for CANF Stock?
CANF stock is predicted to reach **$1.40** by the end of 2025, driven by its recent partnership with Vetbiolix and progress in Phase III trials for liver cancer and psoriasis. However, risks like clinical trial failures could drop it to **$0.90**.
What is price prediction 2030 for CANF Stock?
CANF stock is predicted to reach **$5-7 by 2030**, driven by successful Phase III trial outcomes for Namodenoson and Piclidenoson in liver cancer and psoriasis. However, if trials fail, the price could drop to **$0.50**. The most likely scenario is a moderate increase to **$2-3**.